Drug Profile
AGS 8M4
Alternative Names: AGS-8M4; ASP 6183Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Agensys
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Surface antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Suspended Ovarian cancer
Most Recent Events
- 30 Aug 2010 Astellas Pharma and Agensys terminate a phase I trial [NCT01016054] in Ovarian cancer in USA
- 02 Feb 2010 Phase-II clinical trials in Ovarian cancer in USA (IV)